BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 35485964)

  • 1. lncRNA EGFR-AS1 facilitates leiomyosarcoma progression and immune escape via the EGFR-MYC-PD-L1 axis.
    Chen ML; Fan L; Huang GR; Sun ZF
    Int Immunol; 2022 Jul; 34(7):365-377. PubMed ID: 35485964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thalidomide suppresses angiogenesis and immune evasion via lncRNA FGD5-AS1/miR-454-3p/ZEB1 axis-mediated VEGFA expression and PD-1/PD-L1 checkpoint in NSCLC.
    Xia Y; Wang WC; Shen WH; Xu K; Hu YY; Han GH; Liu YB
    Chem Biol Interact; 2021 Nov; 349():109652. PubMed ID: 34520751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. YY1-induced long non-coding RNA PSMA3 antisense RNA 1 functions as a competing endogenous RNA for microRNA 214-5p to expedite the viability and restrict the apoptosis of bladder cancer cells via regulating programmed cell death-ligand 1.
    Zhang M; Xu Y; Yin S; Qiu F
    Bioengineered; 2021 Dec; 12(2):9150-9161. PubMed ID: 34720049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 5. LncRNA PROX1 antisense RNA 1 promotes PD-L1-mediated proliferation, metastasis, and immune escape in colorectal cancer by interacting with miR-520d.
    Li JS; Liu TM; Li L; Jiang C
    Anticancer Drugs; 2023 Jun; 34(5):669-679. PubMed ID: 36730426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LncRNA PSMB8-AS1 contributes to pancreatic cancer progression via modulating miR-382-3p/STAT1/PD-L1 axis.
    Zhang H; Zhu C; He Z; Chen S; Li L; Sun C
    J Exp Clin Cancer Res; 2020 Sep; 39(1):179. PubMed ID: 32891166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FOXP4-AS1 promotes CD8
    Shen GY; Zhang Y; Huang RZ; Huang ZY; Yang LY; Chen DZ; Yang SB
    Immunol Res; 2024 Apr; ():. PubMed ID: 38687433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular mechanism of lncRNA SNHG12 in immune escape of non-small cell lung cancer through the HuR/PD-L1/USP8 axis.
    Huang Y; Xia L; Tan X; Zhang J; Zeng W; Tan B; Yu X; Fang W; Yang Z
    Cell Mol Biol Lett; 2022 Jun; 27(1):43. PubMed ID: 35658874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipopolysaccharide facilitates immune escape of hepatocellular carcinoma cells via m6A modification of lncRNA MIR155HG to upregulate PD-L1 expression.
    Peng L; Pan B; Zhang X; Wang Z; Qiu J; Wang X; Tang N
    Cell Biol Toxicol; 2022 Dec; 38(6):1159-1173. PubMed ID: 35438468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LncRNA MALAT1 promotes tumorigenesis and immune escape of diffuse large B cell lymphoma by sponging miR-195.
    Wang QM; Lian GY; Song Y; Huang YF; Gong Y
    Life Sci; 2019 Aug; 231():116335. PubMed ID: 30898647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long non-coding RNA HOTTIP enhances IL-6 expression to potentiate immune escape of ovarian cancer cells by upregulating the expression of PD-L1 in neutrophils.
    Shang A; Wang W; Gu C; Chen C; Zeng B; Yang Y; Ji P; Sun J; Wu J; Lu W; Sun Z; Li D
    J Exp Clin Cancer Res; 2019 Sep; 38(1):411. PubMed ID: 31533774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LncRNA OIP5-AS1 Knockdown Facilitated the Ferroptosis and Immune Evasion by Modulating the GPX4 in Oesophageal Carcinoma.
    Hou J; Huang Q; Fan Z; Sang H; Wu S; Cheng S; Li Q
    Comput Math Methods Med; 2022; 2022():8103198. PubMed ID: 35872956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The EGFR-P38 MAPK axis up-regulates PD-L1 through miR-675-5p and down-regulates HLA-ABC via hexokinase-2 in hepatocellular carcinoma cells.
    Liu Z; Ning F; Cai Y; Sheng H; Zheng R; Yin X; Lu Z; Su L; Chen X; Zeng C; Wang H; Liu L
    Cancer Commun (Lond); 2021 Jan; 41(1):62-78. PubMed ID: 34236149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LncRNA
    Xu YJ; Zhao JM; Ni XF; Wang W; Hu WW; Wu CP
    Epigenomics; 2021 Aug; 13(16):1281-1297. PubMed ID: 34523356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LncRNA GATA3-AS1 facilitates tumour progression and immune escape in triple-negative breast cancer through destabilization of GATA3 but stabilization of PD-L1.
    Zhang M; Wang N; Song P; Fu Y; Ren Y; Li Z; Wang J
    Cell Prolif; 2020 Sep; 53(9):e12855. PubMed ID: 32687248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LncRNA FGD5-AS1 promotes the malignant phenotypes of ovarian cancer cells via targeting miR-142-5p.
    Aichen Z; Kun W; Xiaochun S; Lingling T
    Apoptosis; 2021 Jun; 26(5-6):348-360. PubMed ID: 33974163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual targeting of PD-L1 and PD-L2 by PCED1B-AS1 via sponging hsa-miR-194-5p induces immunosuppression in hepatocellular carcinoma.
    Fan F; Chen K; Lu X; Li A; Liu C; Wu B
    Hepatol Int; 2021 Apr; 15(2):444-458. PubMed ID: 33219943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Upregulated LINC01088 facilitates malignant phenotypes and immune escape of colorectal cancer by regulating microRNAs/G3BP1/PD-L1 axis.
    Li C; Pan B; Wang X; Liu X; Qin J; Gao T; Sun H; Pan Y; Wang S
    J Cancer Res Clin Oncol; 2022 Aug; 148(8):1965-1982. PubMed ID: 35357586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LncRNA LOXL1-AS1/miR-let-7a-5p/EGFR-related pathway regulates the doxorubicin resistance of prostate cancer DU-145 cells.
    Bai T; Liu Y; Li B
    IUBMB Life; 2019 Oct; 71(10):1537-1551. PubMed ID: 31188543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KCNQ1OT1 sponges miR-34a to promote malignant progression of malignant melanoma via upregulation of the STAT3/PD-L1 axis.
    Wang X; Ren Z; Xu Y; Gao X; Huang H; Zhu F
    Environ Toxicol; 2023 Feb; 38(2):368-380. PubMed ID: 36399467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.